RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Travere Therapeutics Stock

Travere Therapeutics Equity 2024

Travere Therapeutics Equity

200.81 M USD

Ticker

TVTX

ISIN

US89422G1076

WKN

A2QHYP

In 2024, Travere Therapeutics's equity was 200.81 M USD, a 368.09% increase from the 42.9 M USD equity in the previous year.

Travere Therapeutics Aktienanalyse

What does Travere Therapeutics do?

Travere Therapeutics, Inc is a pharmaceutical company specializing in rare diseases. It was founded in 2019 and is headquartered in San Diego, California. Travere is tirelessly working to develop innovative therapies to improve the lives of patients with rare diseases. History Travere Therapeutics was formed from the merger of Retrophin, Inc and privately held company Censa Pharmaceuticals, Inc. Retrophin was founded in 2011 by Martin Shkreli and had difficulties in developing therapies for rare diseases. Shkreli later left the company and Retrophin focused on developing therapies for multiple rare diseases. In 2019, Retrophin merged with Censa Pharmaceuticals to form Travere Therapeutics, a company solely dedicated to rare diseases. Business Model Travere Therapeutics' business model is to develop innovative therapies for rare diseases that address an unmet medical need. With a strong focus on research and development, the company is working to discover, develop, and market new and life-changing therapies. Travere Therapeutics has a strong pipeline of drugs and medications in various stages of clinical development. This pipeline includes therapies for rare diseases such as nephrotic syndromes, mucopolysaccharidosis, lipid disorders, and others. Divisions Travere Therapeutics specializes in two business areas: pharmaceuticals and diagnostics. Pharmaceutical Business Travere Therapeutics' pharmaceutical business includes researching, developing, and marketing therapies for rare diseases. The company has a strong focus on research and development and has a pipeline of drugs and therapies aimed at improving the lives of patients with rare diseases. Diagnostics Business Travere Therapeutics' diagnostics business focuses on diagnostic tests for rare diseases. The company has partnerships with labs and facilities around the world specializing in diagnostics and genetics to ensure accurate diagnosis of patients with rare diseases. Products Travere Therapeutics offers a variety of products and therapies in different stages of development. Here are some of the key products the company offers: · Isturisa: a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of the hormone cortisol. · Re-PLAI: a medication for the treatment of nephrotic syndromes, a group of disorders caused by kidney dysfunction. · Enzyme Replacement Therapy (ERT): an approach to treating inherited metabolic disorders by administering missing enzymes. Conclusion Travere Therapeutics is an innovative company specializing in developing therapies for rare diseases. The company has a strong pipeline of drugs and the expertise to develop therapies for patients who are underserved by traditional medications. With a focus on research and diagnostics, the company has the potential to improve the lives of millions of patients with rare diseases. Travere Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Travere Therapeutics's Equity

Travere Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Travere Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Travere Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Travere Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Travere Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Travere Therapeutics stock

What is the equity of Travere Therapeutics this year?

Travere Therapeutics has equity of 200.81 M USD this year.

What was the equity of Travere Therapeutics compared to the previous year?

The equity of Travere Therapeutics has increased/decreased by 368.09% increased compared to the previous year.

What impact does a high equity have on investors of Travere Therapeutics?

A high equity is advantageous for investors of Travere Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Travere Therapeutics?

A low equity can be a risk for investors of Travere Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Travere Therapeutics affect the company?

An increase in equity of Travere Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Travere Therapeutics affect the company?

A reduction in equity of Travere Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Travere Therapeutics?

Some factors that can affect the equity of Travere Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Travere Therapeutics so important for investors?

The equity of Travere Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Travere Therapeutics take to change the equity?

To change equity, Travere Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Travere Therapeutics pay?

Over the past 12 months, Travere Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Travere Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Travere Therapeutics?

The current dividend yield of Travere Therapeutics is .

When does Travere Therapeutics pay dividends?

Travere Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Travere Therapeutics?

Travere Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Travere Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Travere Therapeutics located?

Travere Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Travere Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Travere Therapeutics from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.

When did Travere Therapeutics pay the last dividend?

The last dividend was paid out on 7/17/2024.

What was the dividend of Travere Therapeutics in the year 2023?

In the year 2023, Travere Therapeutics distributed 0 USD as dividends.

In which currency does Travere Therapeutics pay out the dividend?

The dividends of Travere Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Travere Therapeutics

Our stock analysis for Travere Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Travere Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.